Please login to the form below

Not currently logged in
Email:
Password:

patisiran

This page shows the latest patisiran news and features for those working in and with pharma, biotech and healthcare.

Alnylam gets EU nod for Onpattro amid pricing backlash

Alnylam gets EU nod for Onpattro amid pricing backlash

The  EMA has cleared Onpattro (patisiran) – the first RNA interference drug approved in the EU – for adult hATTR amyloidosis patients with stage 1 or 2 nerve damage (polyneuropathy), one of the ... intravenous injection of patisiran every three

Latest news

  • ICER says Alnylam’s Onpattro should cost 90%-95% less ICER says Alnylam’s Onpattro should cost 90%-95% less

    In draft guidance, the Institute for Clinical and Economic Review (ICER) says that RNA interference drug Onpattro (patisiran) – and Akcea/Ionis’antisense candidate Tegsedi (inotersen) which is due for an FDA

  • Alnylam claims first RNAi approval from FDA for patisiran Alnylam claims first RNAi approval from FDA for patisiran

    Alnylam claims first RNAi approval from FDA for patisiran. After years of ups and downs, triumph for gene-silencing tech. ... John Maraganore has led Alnylam since 2002. Alnylam’s chief executive – John Maraganore – estimates that there are around 3

  • Alnylam’s amyloidosis drug heads latest crop of CHMP approvals Alnylam’s amyloidosis drug heads latest crop of CHMP approvals

    The EMA’s main advisory committee backed the approval of 16 drugs at its meeting ahead of the weekend, including Alnylam’s patisiran for hereditary transthyretin-mediated (hATTR) amyloidosis. ... The Committee for Medicinal Products for Human Use

  • Alnylam’s amyloidosis drug heads latest crop of CHMP approvals Alnylam’s amyloidosis drug heads latest crop of CHMP approvals

    The EMA’s main advisory committee backed the approval of 16 drugs at its meeting ahead of the weekend, including Alnylam’s patisiran for hereditary transthyretin-mediated (hATTR) amyloidosis. ... The Committee for Medicinal Products for Human Use

  • The year of the blockbuster The year of the blockbuster

    Patisiran from Alnylam and Sanofi: Patisiran is an intravenously administered RNAi therapeutic targeting the transthyretin gene for the treatment of patients with debilitating hereditary transthyretin-mediated amyloidosis. ... The FDA granted patisiran

More from news
Approximately 1 fully matching, plus 14 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics